Anemia of chronic inflammation: Hepcidin,Iron sequestration and Erythropoitin Resistance through the concept of Pandu
Abstract
Anemia of chronic inflammation developes when inflammatory activity restricts iron availability and impairs red -cell production.Hepcidin -mediated iron sequestration is central to this process,but reduced erythropoitin production, altered marrow responsiveness and shortened erythrocyte survival also contribute .These mechanisms complicate the common assumption that anemia necessarily depleted iron stores.
Keywords
Panduanemiaanemia of inflammationHepcidinerythropoitin resistanceIron sequestration
References
1. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf
S, Pedersen BK, et al. IL-6 mediates hypoferremia of
inflammation by inducing the synthesis of the iron
regulatory hormone hepcidin. J Clin Invest.
2004;113(9):1271–1276. doi:10.1172/JCI20945.
2. Nemeth E, Tuttle MS, Powelson J, Vaughn MB,
Donovan A, Ward DM, et al. Hepcidin regulates
cellular iron efflux by binding to ferroportin and
inducing its internalization. Science.
2004;306(5704):2090–2093.
doi:10.1126/science.1104742.
3. Wrighting DM, Andrews NC. Interleukin-6
induces hepcidin expression through STAT3. Blood.
2006;108(9):3204–3209. doi:10.1182/blood-2006-
06-027631.
4. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E,
Ganz T. Identification of erythroferrone as an
erythroid regulator of iron metabolism. Nat Genet.
2014;46(7):678–684. doi:10.1038/ng.2996.
5. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M,
Schroll A, et al. Regulation of iron homeostasis in
anemia of chronic disease and iron deficiency
anemia: diagnostic and therapeutic implications.
Blood. 2009;113(21):5277–5286.
doi:10.1182/blood-2008-12-195651.
6. Baer AN, Dessypris EN, Goldwasser E, Krantz SB.
Blunted erythropoietin response to anemia in
rheumatoid arthritis. Br J Haematol. 1987;66(4):559–
564. doi:10.1111/j.1365-2141.1987.tb01344.x.
7. Faquin WC, Schneider TJ, Goldberg MA. Effect of
inflammatory cytokines on hypoxia-induced
erythropoietin production. Blood. 1992;79(8):1987–
1994.
doi:10.1182/blood.V79.8.1987.bloodjournal7981987
.
8. Libregts SF, Gutiérrez L, de Bruin AM, Wensveen
FM, Papadopoulos P, van Ijcken W, et al. Chronic
IFN-γ production in mice induces anemia by reducing
erythrocyte life span and inhibiting erythropoiesis
through an IRF-1/PU.1 axis. Blood.
2011;118(9):2578–2588. doi:10.1182/blood-2010-
10-315218.9. Khalil S, Delehanty L, Grado S, Holy M, White Z
3rd, Freeman K, et al. Iron modulation of
erythropoiesis is associated with Scribble-mediated
control of the erythropoietin receptor. J Exp Med.
2018;215(2):661–679. doi:10.1084/jem.20170396.
10. World Health Organization. WHO guideline on
use of ferritin concentrations to assess iron status in
individuals and populations [Internet]. Geneva:
World Health Organization; 2020 [cited 2026 Oct
27]. Available from:
https://www.who.int/publications/i/item/978924000
0124
11. van der Vorm LN, Hendriks JCM, Laarakkers
CM, Klaver S, Armitage AE, Bamberg A, et al.
Toward worldwide hepcidin assay harmonization:
identification of a commutable secondary reference
material. Clin Chem. 2016;62(7):993–1001.
doi:10.1373/clinchem.2016.256768.
12. Kidney Disease: Improving Global Outcomes
(KDIGO) Anemia Work Group. KDIGO 2026
Clinical Practice Guideline for the Management of
Anemia in Chronic Kidney Disease (CKD). Kidney
Int. 2026;109(1S):S1–S99.
doi:10.1016/j.kint.2025.06.006.
13. Isaacs JD, Harari O, Kobold U, Lee JS,
Bernasconi C. Effect of tocilizumab on
haematological markers implicates interleukin-6
signalling in the anemia of rheumatoid arthritis.
Arthritis Res Ther. 2013;15:R204.
doi:10.1186/ar4397.
14. Macdougall IC, White C, Anker SD, Bhandari S,
Farrington K, Kalra PA, et al. Intravenous iron in
patients undergoing maintenance hemodialysis. N
Engl J Med. 2019;380(5):447–458.
doi:10.1056/NEJMoa1810742.
15. Pfeffer MA, Burdmann EA, Chen CY, Cooper
ME, de Zeeuw D, Eckardt KU, et al. A trial of
darbepoetin alfa in type 2 diabetes and chronic kidney
disease. N Engl J Med. 2009;361(21):2019–2032.
doi:10.1056/NEJMoa0907845.
16. van Eijk LT, John ASE, Schwoebel F, Summo L,
Vauléon S, Zöllner S, et al. Effect of the antihepcidin
Spiegelmer lexaptepid on inflammation-induced
decrease in serum iron in humans. Blood.
2014;124(17):2643–2646. doi:10.1182/blood-2014-
03-559484.
17. Agnivesha. Charaka Samhita: Pandu Chikitsa,
Chikitsa Sthana, chapter 16, verses 4–6 and 13–16
[Internet]. Charak Samhita Research, Training and
Skill Development Centre; 2020 [cited 2026 Oct 27].
doi:10.47468/CSNE.2020.e01.s06.017. Available
from:
https://carakasamhitaonline.com/index.php?title=Pa
ndu_Chikitsa_Adhyaya
18. Agnivesha. Charaka Samhita: Grahani Chikitsa,
Chikitsa Sthana, chapter 15, verses 27–28 [Internet].
Charak Samhita Research, Training and Skill
Development Centre; 2020 [cited 2026 Oct 27].
doi:10.47468/CSNE.2020.e01.s06.016. Available
from:
https://carakasamhitaonline.com/index.php?title=Gr
ahani_Chikitsa_Adhyaya
19. Prajapati SM, Anand S, Acharya R, Goyal M.
Effect of Opuntia elatior Mill. (Nagaphani) in the
management of Pandu Roga w. s. r to iron deficiency
anemia; an open labeled randomized standard
controlled clinical trial. Ayu. 2020;41(2):87–97.
doi:10.4103/ayu.AYU_31_18.
20. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes
J, Bombardier C; CONSORT Group. Reporting
randomized, controlled trials of herbal interventions:
an elaborated CONSORT statement. Ann Intern Med.
2006;144(5):364–367. doi:10.7326/0003-4819-144-
5-200603070-00013.